Mirna Therapeutics is a biotechnology company located in Austin, Texas. Biotechnology in simple terms is the use of living cells and bacteria to make helpful products. Scientists have discovered many uses for biotechnology, such as processing new medicine, specific cancer research, breakdown of sewage waste and the decomposition process. In agriculture biotechnology can make genetic changes to crop plants used for food products. The list of products that can be improved using biotechnology may be endless as scientists learn more about the cells and bacteria.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Recently, Mirna Therapeutics added a new executive to their Board of Directors. Clay Seagall, Ph.D. as an outside Director. Dr. Seagall is the co-founder, President, CEO, and Chairman of the Board of Directors at Seattle Genetics located in Bothell, Washington which is within the Seattle Metropolitan Area. Seattle Genetics, and Dr. Seagall have developed antibody-based treatments for cancer patients. Seattle Genetics is also working with biotechnology and pharmaceutical companies for their work in oncology, which is a branch of medicine that works with cancer treatment, diagnosis, and prevention.
Mirna Therapeutics is interested in bringing in Dr. Seagall for his leadership and experience with cancer treatments and his ability to raise money for research. He is known to have raised $675 million for research at Seattle Genetics, using public and private financing, that includes the company’s public offering in 2001. Dr. Seagall has a B.S degree in Zoology from the University of Maryland. Furthering his education, he receive a Ph.D in Genetics at George Washington University. During his career, he has written more than seventy publications and has fifteen patents. Most of Dr. Seagall’s focus, and what he brings to all companies he is associated with is his passion for cancer patients, and developing efficient treatments, diagnosis, and prevention of cancer.
Through Dr. Clay Seagall’s leadership, Seattle Genetics has become the leading company developing the antibody-drug conjugates, called ADCs, for cancer treatment. Mirna Therapeutics is a biotechnology company developing microRNA therapeutics, which controls hundreds of genes in the human body. It is believed that miRNA can effect immunity and inflammation as well as embryotic growth, cellular growth and excess growth that can cause cancer. Mirna Therapeutics has already shown success in blocking tumor growth in many pre-clinical animal studies. Adding Dr. Seagall to their Executive Directors should benefit Dr. Seagall and Mirna Therapeutics in the continuing development of miRNA. As this development continues, the benefit should pass on to millions of cancer patients, and the treatment of over 100 types of cancer in humans around the world.